Link: https://cdn.equiruswealth.com/ecpl/uploads/2024/06/Godavari-Biorefineries-Limited-DRHP.pdf
365Telugu.com online news,June 17th,2024:Godavari Biorefineries Limited (“The Company” or “GBL”)one of the prominent manufacturers of ethanol based chemicals in India has filed its Draft Red Herring Prospectus (“DRHP”) with market regulator Securities and Exchange Board of India (“SEBI”).
As on March 31, 2024, the Company has the largest integrated bio-refinery in India in terms of installed capacity and were also the largest manufacturer of MPO (3 Methyl-3 Penten-2-One) worldwide in terms of installed capacity, one of only two manufacturers of natural 1,3 butylene glycol and the only company in India to manufacture bio ethyl acetate according to Frost & Sullivan Report.
The Company plans to raise fund through Equity Share Capital of face value ₹ 10 each. The total issue comprises of fresh issue of equity share aggregating up to ₹ 3,250 million [₹ 325 crore] ”) and offer for sale of up to 6,526,983 Equity Shares. (“Offer For Sale”)
Company plans to utilized the net proceeds from fresh issue towards funding (i) Repayment/pre-payment, in full or in part, of certain outstanding borrowings availed by the Company amounting to ₹ 2,400 million [ ₹ 240 crore] and balance amount towards general corporate purpose. [“Fresh Issue”]
The Offer for Sale comprises of up to 4,926,983 Equity Share by Mandala Capital AG Limited [Investor Selling Shareholders], up to 500,000 Equity Shares by Somaiya Agencies Private Limited, up to 2,00,000 Equity Shares by Samir Shantilal Somaiya, up to 200,000 Equity Shares by Lakshmiwadi Mines and Minerals Private Limited [Promoter Selling Shareholders], up to 300,000 Equity Shares by Filmedia Communication Systems Private Limited, up to 100,000 Equity Shares by Somaiya Properties and Investments Private Limited [Promoter Group Selling Shareholders]. [“The Selling Shareholders”]
Equirus Capital Private Limited and SBI Capital Markets Limited are the Book Running Lead Managers to the IPO. [“BRLMs”]
According to Frost & Sullivan Report the Company has set up India’s first bio-based EVE (Ethyl Vinyl Ethers) manufacturing facility in India as on March 31, 2024 and is poised to capitalize on the import substitution opportunity for EVE in India.
The India market size for the EVE market was approximately 1,258 MT in 2023. Looking forward, the market is expected to grow at a CAGR of 10.0%, reaching to 2,026 MT by 2028. The rise in demand was driven by growing demand from the pharmaceuticals & agrochemicals sector.
Also read :KBC Global Ltd has been awarded a sub contract worth of USD20 Million for soft infrastructure segment from CRJE Ltd
Also read :Alembic Pharmaceuticals announces USFDA Final Approval for Icatibant Injection
Also read : Hyderabad’s popular neighborhood stores now available on PhonePe’s Pincode App
ఇది కూడా చదవండి : హైదరాబాద్ అంతటా ఈద్-ఉల్-అదాను ఘనంగా వేడుకలు
ఇది కూడా చదవండి : బెంగాల్లో గూడ్స్ రైలును కాంచన్జుంగా ఎక్స్ప్రెస్ ఢీకొనడంతో ఐదుగురు మృతి, పలువురు గాయాలు…
ఇది కూడా చదవండి : ఫాదర్స్ డే 2024 ప్రత్యేక సందేశాలు, కోట్స్..